Carregant...

Orally administered anti-eotaxin-1 monoclonal antibody is biologically active in the gut and alleviates immune-mediated hepatitis: A novel anti-inflammatory personalized therapeutic approach

Personalized therapies are designed to optimize the safety-to-efficacy ratio by selecting patients with higher response rates based on specific biomarkers. Inflammation plays a vital role in the pathogenesis of non-alcoholic steatohepatitis (NASH), a common liver disorder. Eotaxin-1 plays a role in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Immunopathol Pharmacol
Autors principals: Khoury, Tawfik, Rotnemer-Golinkin, Dory, Zolotarev, Lidya, Ilan, Yaron
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2021
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8287423/
https://ncbi.nlm.nih.gov/pubmed/34275345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20587384211021215
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!